Prurigo Nodularis Market: Advancing Therapies, Disease Insights, and Future Growth Potential

Narrowband ultraviolet B therapy can help reduce inflammatory responses and itching, while systemic options such as methotrexate, cyclosporine, and azathioprine may be considered for individuals with difficult-to-manage symptoms. Psychological support is also an important component of care because chronic itching and visible skin changes can negatively influence mental health and social functioning.

The expanding prurigo nodularis treatment market is increasingly focused on targeted therapies designed to address specific inflammatory pathways involved in disease development. This shift provides new options for patients who experience inadequate responses with traditional treatment methods.

Prurigo Nodularis Market Impact of DUPIXENT and NEMLUVIO

The introduction of targeted biologic therapies has significantly transformed the therapeutic approach for prurigo nodularis. DUPIXENT (dupilumab), approved for the condition in 2022, works by inhibiting signaling pathways associated with IL-4 and IL-13. NEMLUVIO (nemolizumab), approved in the United States in 2024, targets IL-31 receptor signaling, a pathway strongly associated with chronic itch. Both therapies have expanded treatment options for patients with moderate-to-severe disease.

DelveInsight reports that DUPIXENT generated approximately USD 630 million in US revenue during 2024, making it the leading therapy by current revenue contribution. NEMLUVIO has further strengthened the treatment environment through regulatory approvals across key markets. In February 2025, Galderma received approval from the UK Medicines and Healthcare products Regulatory Agency and the European Commission for NEMLUVIO in adults with moderate-to-severe prurigo nodularis requiring systemic therapy.

Prurigo Nodularis Market Emerging Pipeline Therapies

The pipeline landscape includes multiple investigational therapies that may expand future treatment choices. Povorcitinib from Incyte, an oral JAK1 inhibitor, is being evaluated in Phase III clinical studies and represents growing interest in oral targeted medicines capable of modifying inflammatory pathways.

Other notable pipeline candidates include rocatinlimab from Amgen/Kyowa Kirin, ruxolitinib from Incyte, barzolvolimab from Celldex Therapeutics, and vixarelimab from Kiniksa Pharmaceuticals/Genentech. These therapies target different biological mechanisms associated with inflammation, itch signaling, and lesion development.

Rocatinlimab remains a significant candidate, with Kyowa Kirin indicating in its Q1 2025 presentation that Phase III completion in prurigo nodularis was expected in 2027. Incyte has also reported encouraging clinical findings for povorcitinib, supporting continued advancement of the program.

Prurigo Nodularis Market Growth Drivers and Commercial Opportunities

Several factors are expected to contribute to market expansion through 2034. Increased awareness among dermatologists, improved patient identification, and deeper understanding of disease biology are encouraging pharmaceutical companies to develop therapies with differentiated mechanisms.

The approval of biologic treatments has created a strong foundation for future commercial growth. As additional therapies advance through clinical development, competition is expected to increase while providing physicians with broader choices for individualized patient care.